CoQ10 boosts energy, enhances the immune system, and acts as an antioxidant. Clinical research suggests that using coenzyme Q10 supplements alone or in combination with other drug therapies and nutritional supplements may help prevent or treat some of the following conditions:
Heart disease
Researchers believe that the beneficial effect of CoQ10 in the prevention and treatment of heart disease is due to its ability to improve energy production in cells, inhibit blood clot formation, and act as an antioxidant. One important clinical study, for example, found that people who received daily CoQ10 supplements within 3 days of a heart attack were significantly less likely to experience subsequent heart attacks and chest pain. In addition, these same patients were less likely to die of heart disease than those who did not receive the supplements.
Heart failure (HF)
Levels of CoQ10 are low in people with congestive heart failure (HF), a debilitating disease that occurs when the heart is not able to pump blood effectively. This can cause blood to pool in parts of the body, such as the lungs and legs. Information from several clinical studies suggests that CoQ10 supplements help reduce swelling in the legs, enhance breathing by reducing fluid in the lungs, and increase exercise capacity in people with HF. Not all clinical studies agree, however. As a result, some experts conclude that CoQ10 supplements do not contribute any benefit to the usual conventional treatment for HF. More conclusive research will help resolve the debate.
High blood pressure
Several clinical studies involving small numbers of people suggest that CoQ10 may lower blood pressure. However, it may take 4 - 12 weeks before any beneficial effect is observed. More research with greater numbers of people is needed to assess the value of CoQ10 in the treatment of high blood pressure.
High cholesterol
Levels of CoQ10 tend to be lower in people with high cholesterol compared to healthy individuals of the same age. In addition, certain cholesterol-lowering drugs called statins (such as atorvastatin, cerivastatin, lovastatin, pravastatin, simvastatin) appear to deplete natural levels of CoQ10 in the body. Taking CoQ10 supplements can correct the deficiency caused by statin medications without affecting the medication's positive effects on cholesterol levels.
Diabetes
CoQ10 supplements may improve heart health and blood sugar and help manage high cholesterol and high blood pressure in individuals with diabetes. High blood pressure, high cholesterol, and heart disease are all common problems associated with diabetes. Despite some concern that CoQ10 may cause a sudden and dramatic drop in blood sugar (called hypoglycemia), two recent clinical studies of people with diabetes given CoQ10, 200 mg 2 times daily, showed no hypoglycemic response. If you have diabetes, talk to your doctor or registered dietitian before using CoQ10.
Heart damage caused by chemotherapy
Several clinical studies suggest that CoQ10 may help prevent heart damage caused by certain chemotherapy drugs (namely adriamycin or other athracycline medications). More clinical studies are needed to further evaluate the effectiveness of CoQ10 in preventing heart damage in cancer patients undergoing chemotherapy.
Heart surgery
Clinical research indicates that introducing CoQ10 prior to heart surgery, including bypass surgery and heart transplantation, can reduce damage caused by free radicals, strengthen heart function, and lower the incidence of irregular heart beat (arrhythmias) during the recovery phase.
Breast cancer
Studies of women with breast cancer suggest that CoQ10 supplements (in addition to conventional treatment and a nutritional regimen including other antioxidants and essential fatty acids) may shrink tumors, reduce pain associated with the condition, and cause partial remission in some individuals. It is important to recognize that the beneficial effects these women experienced cannot be attributed to CoQ10 alone. Additional antioxidants used in these studies include vitamins C, E, and selenium.
Periodontal (gum) disease
Gum disease is a widespread problem that is associated with swelling, bleeding, pain, and redness of the gums. Clinical studies have reported that people with gum disease tend to have low levels of CoQ10 in their gums. In a few clinical studies involving small numbers of subjects, CoQ10 supplements caused faster healing and tissue repair. CoQ10 is used in mouth rinse products for this condition. Additional studies in humans are needed to evaluate the effectiveness of CoQ10 when used together with traditional therapy for periodontal disease.
Other
Preliminary clinical studies also suggest that CoQ10 may:
- Improve immune function in individuals with immune deficiencies (such as acquired immunodeficiency syndrome or AIDS) and chronic infections (such as yeast, bacteria, and viral infections)
- Increase sperm motility leading to enhanced fertility
- Be used as part of the treatment for Alzheimer's disease and Parkinson's disease
- Reduce damage from stroke
- Boost athletic performance
- Enhance physical activity in people with fatigue syndromes
- Improve exercise tolerance in individuals with muscular dystrophy
- Improve symptoms of tinnitus, or ringing in the ears
- Be beneficial in cosmetics for healthy skin
- Delay the aging process and increase longevity
Clinical research in all of these areas is underway to determine whether CoQ10 can be safeLy and effectively used in people with these health problems and needs.
Aberg F, Appelkvist EL, Broijersen A, et al. Gemfibrozil-induced decrease in serum ubiquinone and alpha- and gamma-tocopherol levels in men with combined hyperlipidaemia. Eur J Clin Invest. 1998;28:235-242.
Aguilaniu H, Durieux J, Dillin A. Metabolism, ubiquinone synthesis, and longevity. Genes Dev. 2005;19(20):2399-406.
Al-Hasso. Coenzyme Q10: a review. Hosp Pharm. 2001;36(1):51-66.
Alleva R, Scaraarmucci A, Mantera F, Bompandre S, Leoni L, Linarro GP. The protective role of ubiquinol—10 against formation of lipid hydroperoxdes in human seminal fluids. Mol Asp Med. 1997;18:221-228.
Baggio E, Gandini R, Plancher AC, Passeri M, Carmosino G. Italian multicenter study on the safety and efficacy of coenzyme Q10 as adjunctive therapy in heart failure. CoQ10 Drug Surveillance Investigators. Mol Aspects Med. 1994;15(Suppl):s287-294.
Beal MF. Therapeutic effects of coenzyme Q10 in neurodegenerative diseases. Methods Enzymol. 2004;382:473-87.
Belardinelli R, Mucaj A, Lacalaprice F, et al., Coenzyme Q10 and exercise training in chronic heart failure. Eur Heart J. 2006;27(22):2675-81.
Berthold HK, Naini A, Di Mauro S, Hallikainen M, Gylling H, Krone W, Gouni-Berthold I. Effect of ezetimibe and/or simvastatin on coenzyme Q10 levels in plasma: a randomised trial. Drug Saf. 2006;29(8):703-12.
Chello M, Mastroroberto P, Romano R, et al. Protection by coenzyme Q10 from myocardial reperfusion injury during coronary artery bypass grafting. Ann Thorac Surg. 1994;58(5):1427-1432.
Chopra RK, Goldman R, Sinatra ST, Bhagavan HN. Relative bioavailability of coenzyme Q10 formulations in human subjects. Int J Vitam Nutr Res. 1998;68:109-113.
Dhanasekaran M, Ren J. The emerging role of coenzyme Q-10 in aging, neurodegeneration, cardiovascular disease, cancer and diabetes mellitus. Curr Neurovasc Res. 2005;2(5):447-59.
de Bustos F, Molina JA, Jimenez-Jimenz FJ, Garcia-Redondo A, Gomez-Escalonilla C, Porta-Etessam J, et al. Serum levels of coenzyme Q10 in patients with Alzheimer's disease. J Neural Transm. 2000;107(2):233-239.
Eriksson JG. The effects of coenzyme Q10 administration on metabolic control in patients with type 2 diabetes mellitus. Biofactors. 1999;9(2-4):315-318.
Folkers K, Langsjoen P, Nara Y, et al. Biochemical deficiencies of coenzyme Q10 in HIV infection and exploratory treatment. Biochem Biophys Res Commun. 1988;153:888-896.
Hanioka T, Tanaka M, Ojima M, Shizukuishi S, Folkers K. Effect of topical application of coenzyme Q10 on adult periodontitis. Mol Aspects Med. 1994;15 Suppl:s241-248.
Heck AM, DeWitt BA, Lukes AL. Potential interactions between alternative therapies and warfarin. Am J Health-System Pharm. 2000;57(13):1221-1227.
Henriksen J, Andersen CB, Hother-Nielsen O, Vaag A, Mortensen SA, Beck-Nielsen H. Impact of ubiquinone (coenzyme Q10) treatment on glycaemic control, insulin requirement and well-being in patients with type 1 diabetes mellitus. Diabet Med. 1999; 16:312-8.
Human JA, Ubbink JB, Jerling JJ, et al. The effect of simvastatin on the plasma antioxidant concentrations in patients with hypercholesterolemia. Clin Chim Acta. 1997;263(1):67-77.
Iarussi D, Auricchio U, Agretto A, et al. Protective effect of coenzyme Q on anthracylines cardiotoxicity: control study in children with acute lymphoblastic leukemia and non-hodgkin lymphoma. Molec Aspects Med. 1994;15(Suppl):S207-S212.
Jolliet P, Simon N, Barre J, et al. Plasma coenzyme Q10 concentrations in breast cancer: prognosis and therapeutic consequences. Int J Clin Pharmacol Ther. 1998;36:506-509.
Judy WV, Hall JH, Dugan W, et al. Coenzyme Q10 reduction of adriamycin cardiotoxicity. In: Folkes K, Yamamura Y, Eds. Biomedical and clinical aspects of coenzyme Q10, Vol. 4. Amsterdam: Elsevier. 1984:231-241.
Khan M, Gross J, Haupt H, et al., A pilot clinical trial of the effects of coenzyme Q10 on chronic tinnitus aurium. Otolaryngol Head Neck Surg. 2007;136(1):72-7.
Kendler BS. Recent nutritional approaches to prevention and therapy of cardiovascular disease. Prog Cardiovasc Nurs. 1997;12(3):3-23.
Khatta M, Alexander BS, Krichten CM, Fisher ML, Freudenberger R, Robinson SW et al. The effect of conenzyme Q10 in patients with congestive heart failure. Ann Int Med. 2000;132(8):636-640.
Langsjoen P, Langsjoen A. Overview of the use of CoQ10 in cardiovascular disease. BioFactors. 1999;9:273-284.
Langsjoen PH, Langsjoen JO, Langsjoen AM, Lucas LA. Treatment of statin adverse effects with supplemental Coenzyme Q10 and statin drug discontinuation. Biofactors. 2005;25(1-4):147-52.
Langsjoen P, Langsjoen A, Willis R, Folkers K. Treatment of Essential Hypertension with Coenzyme Q10. Molec Aspects Med. 1994;15:s265-s272.
Levy G, Kaufmann P, Buchsbaum R, et al., A two-stage design for a phase II clinical trial of coenzyme Q10 in ALS. Neurology. 2006;66(5):660-3.
Lewin A, Loron M. The effect of coenzyme Q10 on sperm mobility and function. Mol Asp Med. 1997;18:213-219.
Lockwood K, Moesgaard S, Folkers K. Partial and complete regression of breast cancer in patients in relation to dosage of coenzyme Q10. Biochem Biophys Res Commun. 1994;199(3):1504-1508.
Lockwood K, Moesgaard S, Hanioka T, Folkers K. Apparent partial remission of breast cancer in "high risk" patients supplemented with nutritional antioxidants, essential fatty acids, and coenzyme Q10. Mol AspMed. 1994;15 Suppl:s231-s240.
Lockwood K, Moesgaard S, Yamamoto T, Folkers K. Progress in therapy of breast cancer with vitamin Q10 and the regression of metastases. Biochem Biophys Res Commun. 1995;212(1):172-177.
Matthews RT, Yang L, Browne S, Baik M, Beal MF. Coenzyme Q10 administration increases brain mitochondrial concentrations and exerts neuroprotective effects. Proc Natl Acad Sci USA. July 21, 1998; 95:8892-8897.
McCarty MF. Coenzyme Q versus hypertension: does CoQ decrease endothelial superoxide generation? Med Hypotheses. 1999;53:300-304.
McCarty MF. Toward practical prevention of type 2 diabetes. Med Hypotheses. 2000;54(5):786-793.
Miyake Y, Shouza A, Nishikawa M, Yonemoto T, Shimizu H, Omoto S, Hayakawa T, Inada M. Effect of treatment with 3-hydroxy-3methylglutaryl coenzyme A reductase inhibitors on serum coenzyme Q10 in diabetic patients. Arzneimittelforschung. 1999;49(4):324-329.
Mortensen SA, Leth A, Agner E, Rohde M. Dose-related decrease of serum coenzyme Q10 during treatment with HMG-CoA reductase inhibitors. Mol Aspects Med. 1997;18Suppl:S137-S144.
Musumeci O, Naini A, Slonim AE, Skavin N, Hadjigeorgiou GL, Krawiecki N, et al. Familial cerebellar ataxia with muscle coenzyme Q10 deficiency. Neurol. 2001;56(7):849-855.
Niibori K, Yokoyama H, Crestanello JA, Whitman GJ. Acute administration of liposomal coenzyme Q10 increases myocardial tissue levels and improves tolerance to ischemia reperfusion injury. J Surg Res. 1998;79:141-145.
Ostrowski RP. Effect of coenzyme Q(10) on biochemical and morphological changes in experimental ischemia in the rat brain. Brain Res Bull. 2000;53(4):399-407.
Ott BR, Owens NJ. Complementary and alternative medicines for Alzheimer's disease. J Geriatr Psychiatry Neurol. 1998;11:163-173.
Overvad K, Diamant B, Holm L, Holmer G, Mortensen SA, Stender S. Review coenzyme Q10 in health and disease. Eur J Clin Nut. 1999;53:764-770.
Palan PR, Connell K, Ramirez E, Inegbenijie C, Gavara RY, Ouseph JA, Mikhail MS. Effects of menopause and hormone replacement therapy on serum levels of coenzyme Q10 and other lipid-soluble antioxidants. Biofactors. 2005;25(1-4):61-6.
Quinzii CM, Dimauro S, Hirano M. Human coenzyme q(10) deficiency. Neurochem Res. 2007;32(4-5):723-7.
Raitakari OT, McCredie RJ, Witting P, Griffiths KA, Letter J, Sullivan D, Stocker R, Celermajer DS. Coenzyme Q improves LDL resistance to ex vivo oxidation but does not enhance endothelial function in hypercholesterolemic young adults. Free Radic Biol Med. 2000;28(7):1100-1105.
Rosenfeldt F, Hilton D, Pepe S, Krum H. Systematic review of effect of coenzyme Q10 in physical exercise, hypertension and heart failure. Biofactors. 2003;18(1-4):91-100.
Salles JE, Moises VA, Almeida DR, Chacra AR, Moises RS. Myocardial dysfunction in mitochondrial diabetes treated with Coenzyme Q10. Diabetes Res Clin Pract. 2006;72(1):100-3.
Sander S, Coleman CI, Patel AA, Kluger J, White CM. The impact of coenzyme Q10 on systolic function in patients with chronic heart failure. J Card Fail. 2006;12(6):464-72.
Serebruany VL, Ordonez JV, Herzog WR, et al. Dietary coenzyme Q10 supplementation alters platelet size and inhibits human vitronectin (CD51/CD61) receptor expression. J Cardiovasc Pharmacol. 1997;29:16-22.
Shils ME, Olson JA, Shike M, Ross AC. Modern Nutrition in Health and Disease. 9th ed. Baltimore, Md: Williams & Wilkins; 1999:90-92: 1377-1378.
Shinozawa S, Kawasaki H, Gomita Y. [Effect of biological membrane stabilizing drugs (coenzyme Q10, dextran sulfate and reduced glutathione) on adriamycin (doxorubicin)-induced toxicity and microsomal lipid peroxidation in mice]. Gan To Kagaku Ryoho. 1996;23(1):93-98.
Shults CW, Haas R. Clinical trials of coenzyme Q10 in neurological disorders. Biofactors. 2005;25(1-4):117-26.
Shults CW. Therapeutic role of coenzyme Q(10) in Parkinson's disease. Pharmacol Ther. 2005;107(1):120-30.
Sinclair S. Male infertility: nutritional and environmental considerations. Alt Med Rev. 2000;5(1):28-37.
Singh RB, Niaz MA, Rastogi SS, Shukla PK, Thakur AS. Effect of hydrosoluble coenzyme Q10 on blood pressures and insulin resistance in hypertensive patients with coronary artery disease. J Hum Hypertens. 1999;13(3):203-208.
Singh RB, Wander GS, Rastogi A, et al. Randomized, double-blind placebo-controlled trial of coenzyme Q10 in patients with acute myocardial infarction. Cardiovasc Drugs Ther. 1998;12:347-353.
Spigset O. Reduced effect of warfarin caused by ubidecarenone. Lancet. 1994;344:1372-1373.
Takahashi N, Iwasaka T, Sugiura T, et al. Effect of coenzyme Q10 on hemodynamic response to ocular timolol. J Cardiovasc Pharmacol. 1989;14:462-468.
Torkos S. Drug-nutrient interactions: A focus on cholesterol-lowering agents. Int J Integrative Med. 2000;2(3):9-13.
Tsukahara Y, Wakatsuki A, Okatani Y. Antioxidant role of endogenaous coenzyme Q against the iscemic and reperfusion-induced lipid peroxidation in fetal rat brain. Acta Obstet Gynecol Scand. 1999;78(8):669-674.
Weant KA, Smith KM. The role of coenzyme Q10 in heart failure. Ann Pharmacother. 2005;39(9):1522-6.
Wilkinson EG, Arnold RM, Folkers K. Treatment of periodontal and other soft tissue diseases in the oral cavity with coenzyme Q10. In: Folker K, Yamamura Y, eds. Biomedical and Clinical Aspects of Coenzyme Q10, Vol 1. Elsevier/North-Holland Biomedical Press;Amsterdam, 1977:251-265.
Witte KK, Clark AL, Cleland JG. Chronic heart failure and micronutrients. J Am Coll Cardiol. 2001;37(7):1765-1774.
Zhou Q, Chan E. Accuracy of repeated blood sampling in rats: A new technique applied in pharmacokinetic/pharmacodynamic studies of the interaction between warfarin and Co-enzyme Q10. J Pharmacol Toxicol Methods. 1998;40(4):191-199.